Research and Development

The Research and Development team at Pharvaris is responsible for advancing the discovery and development of novel oral bradykinin B2 receptor antagonists for hereditary angioedema. This multidisciplinary team leverages expertise in toxicology, pharmacology, and biostatistics to evaluate the safety and efficacy of new compounds through preclinical and clinical stages, ensuring compliance with regulatory standards while guiding innovative research initiatives. Their work is pivotal in transforming promising small molecules into viable therapeutic options for patients.